Posted: Thursday, June 16, 2022
The central nervous system (CNS)-active TRK inhibitor entrectinib appears to provide deep and durable systemic and intracranial responses in patients with advanced NTRK fusion–positive solid tumors with or without baseline CNS metastases, according to the updated results of an integrated analysis of three phase I/II trials. Maciej Jerzy Krzakowski, MD, PhD, of the Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, and colleagues presented these study updates at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 3099).
This analysis, comprising data from three studies (ALKA-372-001, STARTRK-1, and STARTRK-2), included 150 patients with locally advanced or metastatic NTRK fusion–positive solid tumors and at least 12 months of follow-up from the first tumor assessment. The median patient age in the study cohort was 58.5 years. The cohort study represented 17 different types of solid tumors, including sarcoma, non–small cell lung, mammary analog secretory, thyroid, breast, head/neck, and neuroendocrine.
The objective response rate was 61.3%, including 25 complete responses; responses were observed in all tumor types represented by at least two patients. The median duration of response, progression-free survival, and overall survival were 20.0 months, 13.8 months, and 37.1 months, respectively. In patients with measurable CNS metastases, the intracranial objective response rate was 69.2%; the median intracranial duration of response was 17.2 months.
Overall, treatment with entrectinib was reported to be well tolerated. In the safety population (n = 235), the most frequent treatment-related adverse events were dysgeusia (36.6%), diarrhea (29.8%), and weight increase (28.5%).
Disclosure: For full disclosures of the study authors, visit coi.asco.org.